SB05 (EndoTAG®-1) is approved to conduct Phase III clinical trial for pancreatic cancer in Israel.
SynCore has submitted to implement the clinical trial in several countries. Until now, SynCoreBio has successfully passed the verification from Taiwan, U.S., France, Hungary, Russia, and South Korea. We have started to prepare for the following process, anticipated to accelerate into the recruiting process.
SynCore has submitted to implement the clinical trial in several countries. Until now, SynCoreBio has successfully passed the verification from Taiwan, U.S., France, Hungary, Russia, and South Korea. We have started to prepare for the following process, anticipated to accelerate into the recruiting process.
| No. | Country | Status |
| 1 | USA |
Phase III clinical trial. |
| 2 | Taiwan | |
| 3 | France | |
| 4 | Hungary | |
| 5 | South Korea | |
| 6 | Russia | |
| 7 | Israel |
About SynCore Biotechnology Co., Ltd
SynCore Biotechnology Co., Ltd (“SynCore”) is a biopharmaceutical company focusing on creating values of new drugs by R&D and integration of technology resources. SynCore was established in 2008 and cofounded by Sinphar Group and National Health Research Institute (NHRI). SynCore utilizes and in-licenses the unique technologies from all over the world to develop new drugs for unmet medical needs with great marketing potential. Syncore’s comprehensive pipeline portfolio of new drugs in the area of oncology, ophthalmology, dermatology and infectious diseases.
Meet us at:
- CBIIC, China, Sep. 2018
- Bio Partnering APAC, China, Sep. 2018
- Bio Europe, Denmark, Nov. 2018